These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 32799295)
21. Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial. Ritsinger V; Malmberg K; Mårtensson A; Rydén L; Wedel H; Norhammar A Lancet Diabetes Endocrinol; 2014 Aug; 2(8):627-33. PubMed ID: 24831989 [TBL] [Abstract][Full Text] [Related]
22. Rationale and design of the LIBERATES trial: Protocol for a randomised controlled trial of flash glucose monitoring for optimisation of glycaemia in individuals with type 2 diabetes and recent myocardial infarction. Everett CC; Reynolds C; Fernandez C; Stocken DD; Sharples LD; Sathyapalan T; Heller S; Storey RF; Ajjan RA Diab Vasc Dis Res; 2020; 17(5):1479164120957934. PubMed ID: 33081502 [TBL] [Abstract][Full Text] [Related]
23. Avoiding hypoglycaemia while achieving good glycaemic control in type 2 diabetes through optimal use of oral agent therapy. Barnett AH Curr Med Res Opin; 2010 Jun; 26(6):1333-42. PubMed ID: 20370379 [TBL] [Abstract][Full Text] [Related]
24. Association between the extent of urinary albumin excretion and glycaemic variability indices measured by continuous glucose monitoring. Jin SM; Kim TH; Oh S; Baek J; Joung JY; Park SM; Cho YY; Sohn SY; Hur KY; Lee MS; Lee MK; Kim JH Diabet Med; 2015 Feb; 32(2):274-9. PubMed ID: 25307609 [TBL] [Abstract][Full Text] [Related]
25. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain: 52-week data from the PREDICTIVE study in a cohort of French patients with type 1 or type 2 diabetes. Marre M; Pinget M; Gin H; Thivolet C; Hanaire H; Robert JJ; Fontaine P Diabetes Metab; 2009 Dec; 35(6):469-75. PubMed ID: 19914118 [TBL] [Abstract][Full Text] [Related]
26. The reality of glycaemic control in insulin treated diabetes: defining the clinical challenges. Davies M Int J Obes Relat Metab Disord; 2004 Sep; 28 Suppl 2():S14-22. PubMed ID: 15306833 [TBL] [Abstract][Full Text] [Related]
27. Prevalence of dysglycaemic events among inpatients with diabetes mellitus: a Singaporean perspective. Ong KY; Kwan YH; Tay HC; Tan DS; Chang JY Singapore Med J; 2015 Jul; 56(7):393-400. PubMed ID: 26243976 [TBL] [Abstract][Full Text] [Related]
28. Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes? Nattrass M; Lauritzen T Int J Obes Relat Metab Disord; 2000 Sep; 24 Suppl 3():S21-31. PubMed ID: 11063281 [TBL] [Abstract][Full Text] [Related]
29. Intensive glucose therapy and clinical implications of recent data: a consensus statement from the Global Task Force on Glycaemic Control. Akalin S; Berntorp K; Ceriello A; Das AK; Kilpatrick ES; Koblik T; Munichoodappa CS; Pan CY; Rosenthall W; Shestakova M; Wolnik B; Woo V; Yang WY; Yilmaz MT; Int J Clin Pract; 2009 Oct; 63(10):1421-5. PubMed ID: 19769698 [TBL] [Abstract][Full Text] [Related]
30. Insulin degludec--the impact of a new basal insulin on care in type 2 diabetes. Khunti K; Cos X; Rutten G Prim Care Diabetes; 2014 Jul; 8(2):119-25. PubMed ID: 24207030 [TBL] [Abstract][Full Text] [Related]
31. Trend of antihyperglycaemic therapy and glycaemic control in 184,864 adults with type 1 or 2 diabetes between 2002 and 2014: Analysis of real-life data from the DPV registry from Germany and Austria. Bohn B; Kerner W; Seufert J; Kempe HP; Jehle PM; Best F; Füchtenbusch M; Knauerhase A; Hofer M; Rosenbauer J; Holl RW; Diabetes Res Clin Pract; 2016 May; 115():31-8. PubMed ID: 27242120 [TBL] [Abstract][Full Text] [Related]
32. Novel approaches to the treatment of hyperglycaemia in type 2 diabetes mellitus. Galligan A; Greenaway TM Intern Med J; 2016 May; 46(5):540-9. PubMed ID: 27170238 [TBL] [Abstract][Full Text] [Related]
33. Insulin degludec allows for better glycaemic control with a lower risk of hypoglycaemia in patients with chronic kidney disease and type 2 diabetes. Dolores García de Lucas M; Avilés Bueno B; Rivas Ruiz F; Olalla Sierra J Diabetes Res Clin Pract; 2020 Apr; 162():108094. PubMed ID: 32113852 [TBL] [Abstract][Full Text] [Related]
34. Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy. Hirsch IB; Buse JB; Leahy J; McGill JB; Peters A; Rodbard HW; Rubin RR; Skyler JS; Verderese CA; Riddle MC Diabetes Obes Metab; 2014 Mar; 16(3):206-14. PubMed ID: 23711193 [TBL] [Abstract][Full Text] [Related]
35. Prescribing in type 2 diabetes: choices and challenges. Hill J Nurs Stand; 2010 Oct 6-12; 25(5):55-6, 58. PubMed ID: 21133019 [TBL] [Abstract][Full Text] [Related]
36. Use of nutrition therapy in the management of diabetes mellitus. Abu-Qamar MZ Nurs Stand; 2019 Feb; 34(3):61-66. PubMed ID: 31468927 [TBL] [Abstract][Full Text] [Related]
37. [Optimisation of pharmacological therapy in a patient with a newly diagnosed type 2 diabetes]. De Flines J; Radermecker RP; Jandrain BJ; Scheen AJ Rev Med Liege; 2009 Feb; 64(2):109-14. PubMed ID: 19370857 [TBL] [Abstract][Full Text] [Related]
38. Reducing hypoglycaemia with insulin analogues. Heller S Int J Obes Relat Metab Disord; 2002 Sep; 26 Suppl 3():S31-6. PubMed ID: 12174321 [TBL] [Abstract][Full Text] [Related]
39. Amylin and glycaemic regulation: a possible role for the human amylin analogue pramlintide. Kolterman OG Diabet Med; 1997 Jun; 14 Suppl 2():S35-8. PubMed ID: 9212328 [TBL] [Abstract][Full Text] [Related]
40. Glycaemic control in insulin requiring diabetes patients receiving exclusive enteral tube feeding in an acute hospital setting. Murphy PM; Moore E; Flanagan DE Diabetes Res Clin Pract; 2014 Mar; 103(3):426-9. PubMed ID: 24462281 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]